Cochrane · systematic review · CD002830
Droperidol for psychosis‐induced aggression or agitation
Khokhar, MA, Rathbone, J · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
19
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 9 · 32.1%Very low 0 · 0%Low 5 · 17.9%Moderate 5 · 17.9%High 9 · 32.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Droperidol versus placebo
Population: acute psychosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes Droperidol vs placebo | RR 1.18 [1.05, 1.31] | 1 study · 227 participants | High |
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) Droperidol vs placebo | RR 0.55 [0.36, 0.85] | 1 study · 227 participants | High |
Adverse effects ‐ cardiovascular ‐ arrhythmia Droperidol vs placebo | RR 0.34 [0.01, 8.31] | 1 study · 227 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ respiratory ‐ airway obstruction Droperidol vs placebo | RR 0.62 [0.15, 2.52] | 1 study · 227 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Service use: person able to be discharged home Droperidol vs placebo | RR 1.16 [0.9, 1.48] | 1 study · 227 participants | High |
Mental state ‐ improvement Droperidol vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic: direct costs Droperidol vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Droperidol versus haloperidol
Population: acute psychosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes Droperidol vs haloperidol | RR 1.01 [0.93, 1.09] | 1 study · 228 participants | High |
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) Droperidol vs haloperidol | RR 0.37 [0.16, 0.9] | 2 studies · 255 participants | High |
Adverse effects ‐ cardiovascular ‐ hypotension Droperidol vs haloperidol | RR 2.8 [0.3, 26.49] | 1 study · 228 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ cardiovascular ‐ hypotension/desaturation Droperidol vs haloperidol | RR 2.8 [0.12, 67.98] | 1 study · 228 participants | Low Downgraded: risk of bias |
Service use: person able to be discharged home Droperidol vs haloperidol | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) Droperidol vs haloperidol | MD 0.11 | 1 study · 40 participants | Low Downgraded: risk of bias |
Economic: direct costs Droperidol vs haloperidol | no estimate extracted | 0 studies · 0 participants | Ungraded |
Droperidol versus midazolam
Population: acute psychosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep: tranquillised/asleep ‐ by 30 minutes (at 10 minutes) Droperidol vs midazolam | RR 0.96 [0.72, 1.28] | 1 study · 153 participants | High |
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) Droperidol vs midazolam | RR 0.54 [0.24, 1.2] | 1 study · 153 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ respiratory ‐ airway obstruction Droperidol vs midazolam | RR 0.13 [0.01, 2.55] | 1 study · 153 participants | Low Downgraded: risk of bias |
Adverse effects ‐ respiratory ‐ hypoxia Droperidol vs midazolam | RR 0.7 [0.16, 3.03] | 1 study · 153 participants | Moderate Downgraded: risk of bias |
Service use: person able to be discharged home Droperidol vs midazolam | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state ‐ improvement Droperidol vs midazolam | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic: direct costs Droperidol vs midazolam | no estimate extracted | 0 studies · 0 participants | Ungraded |
Droperidol versus olanzapine
Population: acute psychosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep: tranquillised/asleep ‐ by around 30 minutes Droperidol vs olanzapine | RR 1.02 [0.94, 1.11] | 1 study · 221 participants | High |
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) Droperidol vs olanzapine | RR 0.56 [0.36, 0.87] | 1 study · 221 participants | High |
Adverse effects ‐ cardiovascular ‐ arrhythmia Droperidol vs olanzapine | RR 0.32 [0.01, 7.88] | 1 study · 221 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ respiratory ‐ airway obstruction Droperidol vs olanzapine | RR 0.97 [0.2, 4.72] | 1 study · 221 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Service use: person able to be discharged home Droperidol vs olanzapine | RR 1.06 [0.83, 1.34] | 1 study · 221 participants | High |
Mental state ‐ improvement Droperidol vs olanzapine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic: direct costs Droperidol vs olanzapine | no estimate extracted | 0 studies · 0 participants | Ungraded |